Eiger Biopharmaceuticals Stock Price, News & Analysis (NASDAQ:EIGR)

$8.45 -0.05 (-0.59 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$8.45
Today's Range$8.35 - $8.68
52-Week Range$6.10 - $16.20
Volume47,541 shs
Average Volume229,945 shs
Market Capitalization$88.86 million
P/E Ratio-1.59
Dividend YieldN/A
Beta1.91

About Eiger Biopharmaceuticals (NASDAQ:EIGR)

Eiger Biopharmaceuticals logoEiger BioPharmaceuticals, Inc., formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema. Lonafarnib is an orally active inhibitor of farnesyl transferase that inhibits the prenylation step of HDV replication inside liver cells and blocks the ability of the virus to multiply. It is conducting over three Phase II clinical trials, which include LOnafarnib With and without Ritonavir (LOWR) HDV-2 (Ankara, Turkey), LOWR HDV-3 (NIH) and LOWR HDV-4 (Hannover, Germany). Exendin is in Phase II clinical studies for the treatment of hypoglycemia associated with bariatric surgery. Ubenimex is in Phase II clinical studies for the treatment of PAH and lymphedema.

Receive EIGR News and Ratings via Email

Sign-up to receive the latest news and ratings for EIGR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:EIGR
CUSIPN/A
Phone+1-650-2799845

Debt

Debt-to-Equity Ratio1.19%
Current Ratio5.78%
Quick Ratio5.78%

Price-To-Earnings

Trailing P/E Ratio-1.59433962264151
Forward P/E Ratio-1.85
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.87 per share
Price / Book1.74

Profitability

Trailing EPS($5.30)
Net Income$-47,080,000.00
Net MarginsN/A
Return on Equity-169.16%
Return on Assets-95.71%

Miscellaneous

Employees20
Outstanding Shares10,520,000

Eiger Biopharmaceuticals (NASDAQ:EIGR) Frequently Asked Questions

What is Eiger Biopharmaceuticals' stock symbol?

Eiger Biopharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."

How were Eiger Biopharmaceuticals' earnings last quarter?

Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) released its quarterly earnings results on Thursday, November, 9th. The biotechnology company reported ($1.10) EPS for the quarter, beating the Zacks' consensus estimate of ($1.28) by $0.18. View Eiger Biopharmaceuticals' Earnings History.

When will Eiger Biopharmaceuticals make its next earnings announcement?

Eiger Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March, 21st 2018. View Earnings Estimates for Eiger Biopharmaceuticals.

Where is Eiger Biopharmaceuticals' stock going? Where will Eiger Biopharmaceuticals' stock price be in 2018?

7 analysts have issued 1-year price targets for Eiger Biopharmaceuticals' shares. Their predictions range from $17.00 to $35.00. On average, they expect Eiger Biopharmaceuticals' share price to reach $29.00 in the next twelve months. View Analyst Ratings for Eiger Biopharmaceuticals.

What are Wall Street analysts saying about Eiger Biopharmaceuticals stock?

Here are some recent quotes from research analysts about Eiger Biopharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Eiger BioPharmaceuticals, Inc. is a biopharmaceutical company which develops and manufactures drugs and therapies for the treatment of orphan diseases. Eiger BioPharmaceuticals, Inc., formerly known as Celladon Corporation, is based in Palo Alto, California. " (2/20/2018)
  • 2. Wedbush analysts commented, "The Wedbush View: With four drug candidates being tested in four indications and enough cash runway to cover data readouts over the next 12 months, we believe EIGR is trading at an attractive value and recommend shares to investors." (6/21/2017)

Who are some of Eiger Biopharmaceuticals' key competitors?

Who are Eiger Biopharmaceuticals' key executives?

Eiger Biopharmaceuticals' management team includes the folowing people:

  • David A Cory, President, Chief Executive Officer, Director (Age 52)
  • James H. Welch, Chief Financial Officer (Age 58)
  • David Apelian M.D., Ph.D., Chief Operating Officer and Executive Medical Officer and Director (Age 51)
  • Rebecque J. Laba, Vice President - Corporate Operations (Age 53)
  • Jeffrey J. Rudy, Vice President - Clinical Operations (Age 53)
  • Ryan K. Takeya, Vice President - Manufacturing (Age 46)
  • James P. Shaffer, Chief Business Officer (Age 49)
  • Thomas J. Dietz, Director
  • Jeffrey S. Glenn, Director
  • Evan Loh M.D., Director

Who owns Eiger Biopharmaceuticals stock?

Eiger Biopharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Prosight Management LP (6.45%), Jennison Associates LLC (5.74%), Sphera Funds Management LTD. (4.86%), Armistice Capital LLC (3.65%), Stonepine Capital Management LLC (1.43%) and P.A.W. Capital Corp (0.95%). Company insiders that own Eiger Biopharmaceuticals stock include James H Welch, James P Shaffer, Jeffrey S Glenn and Ventures Fund Vi LP Vivo. View Institutional Ownership Trends for Eiger Biopharmaceuticals.

Who sold Eiger Biopharmaceuticals stock? Who is selling Eiger Biopharmaceuticals stock?

Eiger Biopharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Sabby Management LLC, Millennium Management LLC and Sphera Funds Management LTD.. View Insider Buying and Selling for Eiger Biopharmaceuticals.

Who bought Eiger Biopharmaceuticals stock? Who is buying Eiger Biopharmaceuticals stock?

Eiger Biopharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Prosight Management LP, Jennison Associates LLC, Armistice Capital LLC, Stonepine Capital Management LLC, Unterberg Capital LLC, P.A.W. Capital Corp and Renaissance Technologies LLC. Company insiders that have bought Eiger Biopharmaceuticals stock in the last two years include James H Welch, James P Shaffer, Jeffrey S Glenn and Ventures Fund Vi LP Vivo. View Insider Buying and Selling for Eiger Biopharmaceuticals.

How do I buy Eiger Biopharmaceuticals stock?

Shares of Eiger Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eiger Biopharmaceuticals' stock price today?

One share of Eiger Biopharmaceuticals stock can currently be purchased for approximately $8.45.

How big of a company is Eiger Biopharmaceuticals?

Eiger Biopharmaceuticals has a market capitalization of $88.86 million. The biotechnology company earns $-47,080,000.00 in net income (profit) each year or ($5.30) on an earnings per share basis. Eiger Biopharmaceuticals employs 20 workers across the globe.

How can I contact Eiger Biopharmaceuticals?

Eiger Biopharmaceuticals' mailing address is 350 Cambridge Ave Ste 350, PALO ALTO, CA 94306-1577, United States. The biotechnology company can be reached via phone at +1-650-2799845 or via email at [email protected]


MarketBeat Community Rating for Eiger Biopharmaceuticals (EIGR)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  224 (Vote Outperform)
Underperform Votes:  141 (Vote Underperform)
Total Votes:  365
MarketBeat's community ratings are surveys of what our community members think about Eiger Biopharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Eiger Biopharmaceuticals (NASDAQ:EIGR) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $29.00$29.00$33.00$32.60
Price Target Upside: 81.25% upside81.25% upside194.64% upside307.50% upside

Eiger Biopharmaceuticals (NASDAQ:EIGR) Consensus Price Target History

Price Target History for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Eiger Biopharmaceuticals (NASDAQ:EIGR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/16/2018OppenheimerSet Price TargetBuy$26.00HighView Rating Details
1/16/2018Piper Jaffray CompaniesReiterated RatingOverweight$35.00 -> $17.00HighView Rating Details
1/3/2018Ladenburg Thalmann Financial ServicesInitiated CoverageBuy -> Buy$32.00HighView Rating Details
10/25/2017WedbushReiterated RatingBuyN/AView Rating Details
10/19/2017Roth CapitalInitiated CoverageBuy -> Buy$35.00N/AView Rating Details
7/14/2017BTIG ResearchInitiated CoverageBuy$32.00HighView Rating Details
5/15/2017Jefferies GroupReiterated RatingBuy$28.00 -> $27.00MediumView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Eiger Biopharmaceuticals (NASDAQ:EIGR) Earnings History and Estimates Chart

Earnings by Quarter for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Eiger Biopharmaceuticals (NASDAQ EIGR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/21/2018($1.02)N/AView Earnings Details
11/9/2017Q3 2017($1.28)($1.10)ViewN/AView Earnings Details
8/14/2017Q2 2017($1.28)($1.33)ViewN/AView Earnings Details
5/12/2017Q1 2017($1.35)($1.34)ViewN/AView Earnings Details
3/23/2017Q4 2016($1.38)($1.53)ViewN/AView Earnings Details
11/8/2016Q3 2016($1.21)($1.49)ViewN/AView Earnings Details
8/10/2016Q2($1.17)($1.87)ViewN/AView Earnings Details
5/16/2016Q1($1.69)($10.42)ViewN/AView Earnings Details
11/9/2015Q3 2015($3.30)($4.05)ViewN/AView Earnings Details
8/11/2015Q2($0.32)($0.69)ViewN/AView Earnings Details
5/14/2015Q1 2015($6.90)($10.64)ViewN/AView Earnings Details
3/31/2015Q414($0.36)($0.49)ViewN/AView Earnings Details
11/12/2014Q3 2014($0.39)($0.40)ViewN/AView Earnings Details
8/7/2014Q2 2014($0.39)($0.38)ViewN/AView Earnings Details
5/13/2014Q1 2014($0.44)($0.58)ViewN/AView Earnings Details
3/31/2014Q4 2013($0.47)($7.96)ViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Eiger Biopharmaceuticals (NASDAQ:EIGR) Earnings Estimates

2018 EPS Consensus Estimate: ($3.42)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.87)($0.87)($0.87)
Q2 20181($0.86)($0.86)($0.86)
Q3 20181($0.85)($0.85)($0.85)
Q4 20181($0.84)($0.84)($0.84)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Eiger Biopharmaceuticals (NASDAQ:EIGR)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Eiger Biopharmaceuticals (NASDAQ EIGR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 28.80%
Institutional Ownership Percentage: 61.59%
Insider Trades by Quarter for Eiger Biopharmaceuticals (NASDAQ:EIGR)
Insider Trades by Quarter for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Eiger Biopharmaceuticals (NASDAQ EIGR) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/1/2017Jeffrey S GlennDirectorBuy15,000$9.53$142,950.0031,355View SEC Filing  
11/18/2016Jeffrey S GlennDirectorBuy15,460$12.74$196,960.4016,355View SEC Filing  
8/18/2016James P ShafferInsiderBuy3,125$15.70$49,062.505,620View SEC Filing  
8/18/2016Ventures Fund Vi L.P. VivoMajor ShareholderBuy187,500$16.00$3,000,000.00View SEC Filing  
6/22/2016James H WelchCFOBuy2,500$19.80$49,500.002,000View SEC Filing  
6/13/2016James P ShafferInsiderBuy1,250$22.17$27,712.501,975View SEC Filing  
5/23/2016James P ShafferInsiderBuy1,245$19.80$24,651.00500View SEC Filing  
4/6/2015Krisztina M ZseboCEOSell47,931$18.20$872,344.20View SEC Filing  
4/2/2015Rebecque J LabaVPSell11,012$17.30$190,507.60View SEC Filing  
3/9/2015Krisztina M ZseboCEOSell47,931$24.80$1,188,688.80View SEC Filing  
3/6/2015Peter HonigDirectorSell9,700$23.74$230,278.00View SEC Filing  
3/6/2015Rebecque J LabaVPSell14,000$23.06$322,840.00View SEC Filing  
3/2/2015Ryan K TakeyaVPSell7,777$18.48$143,718.96View SEC Filing  
2/9/2015Krisztina M ZseboCEOSell47,931$15.86$760,185.66View SEC Filing  
2/6/2015Rebecque J LabaVPSell14,000$16.08$225,120.00View SEC Filing  
2/2/2015Ryan K TakeyaVPSell7,777$16.35$127,153.95View SEC Filing  
1/9/2015Jeffrey J RudyVPSell10,000$18.51$185,100.00View SEC Filing  
1/7/2015Rebecque J LabaVPSell20,000$17.30$346,000.00View SEC Filing  
1/6/2015Krisztina M ZseboCEOSell41,302$17.51$723,198.02View SEC Filing  
1/2/2015Ryan K TakeyaVPSell7,777$19.88$154,606.76View SEC Filing  
12/9/2014Jeffrey J RudyVPSell10,000$15.00$150,000.00View SEC Filing  
12/9/2014Krisztina M ZseboCEOSell41,302$15.00$619,530.00View SEC Filing  
12/5/2014Rebecque J LabaVPSell20,000$12.77$255,400.00View SEC Filing  
12/1/2014Ryan K TakeyaVPSell7,777$12.01$93,401.77View SEC Filing  
2/4/2014Enterprise Partners ManagementMajor ShareholderBuy133,083$8.00$1,064,664.00View SEC Filing  
2/4/2014Fredrik WiklundVPBuy20,000$8.00$160,000.00View SEC Filing  
2/4/2014Todd FoleyDirectorBuy111,608$8.00$892,864.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Eiger Biopharmaceuticals (NASDAQ EIGR) News Headlines

Source:
DateHeadline
Eiger Biopharmaceuticals (EIGR) Lowered to Hold at Zacks Investment ResearchEiger Biopharmaceuticals (EIGR) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - February 20 at 10:40 PM
Eiger BioPharmaceuticals to Participate in Two Upcoming Investor Conferences in FebruaryEiger BioPharmaceuticals to Participate in Two Upcoming Investor Conferences in February
finance.yahoo.com - February 6 at 9:28 AM
Comparing Jaguar Health (JAGX) & Eiger Biopharmaceuticals (EIGR)Comparing Jaguar Health (JAGX) & Eiger Biopharmaceuticals (EIGR)
www.americanbankingnews.com - February 4 at 5:16 AM
Eiger Biopharmaceuticals Inc (EIGR) Given Consensus Rating of "Buy" by BrokeragesEiger Biopharmaceuticals Inc (EIGR) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - January 30 at 7:56 AM
 Analysts Expect Eiger Biopharmaceuticals Inc (EIGR) Will Post Earnings of -$1.02 Per Share Analysts Expect Eiger Biopharmaceuticals Inc (EIGR) Will Post Earnings of -$1.02 Per Share
www.americanbankingnews.com - January 21 at 11:26 AM
These Two Biotechs Just Reported Key DataThese Two Biotechs Just Reported Key Data
finance.yahoo.com - January 19 at 10:29 AM
Eiger BioPharmaceuticals Inc. (EIGR) Is Sinking After Phase 2 Study FailedEiger BioPharmaceuticals Inc. (EIGR) Is Sinking After Phase 2 Study Failed
www.nasdaq.com - January 16 at 5:22 PM
Why Eiger BioPharma Shares Are Getting CrushedWhy Eiger BioPharma Shares Are Getting Crushed
finance.yahoo.com - January 16 at 5:22 PM
Eiger BioPharmaceuticals (EIGR) Says Phase 2 LIBERTY Study in Pulmonary Arterial Hypertension Did Not Meet Primary EndpointEiger BioPharmaceuticals (EIGR) Says Phase 2 LIBERTY Study in Pulmonary Arterial Hypertension Did Not Meet Primary Endpoint
www.streetinsider.com - January 16 at 9:28 AM
Eiger shares plummet 40% after phase 2 trial failureEiger shares plummet 40% after phase 2 trial failure
finance.yahoo.com - January 16 at 9:28 AM
Eiger BioPharmaceuticals Announces Phase 2 LIBERTY Study in Pulmonary Arterial Hypertension Did Not Meet Primary EndpointEiger BioPharmaceuticals Announces Phase 2 LIBERTY Study in Pulmonary Arterial Hypertension Did Not Meet Primary Endpoint
finance.yahoo.com - January 16 at 9:28 AM
Galectin Therapeutics (GALT) and Eiger Biopharmaceuticals (EIGR) Head to Head ComparisonGalectin Therapeutics (GALT) and Eiger Biopharmaceuticals (EIGR) Head to Head Comparison
www.americanbankingnews.com - January 10 at 11:14 PM
Eiger BioPharmaceuticals (EIGR) Appoints Eldon Mayer to Board - StreetInsider.comEiger BioPharmaceuticals (EIGR) Appoints Eldon Mayer to Board - StreetInsider.com
www.streetinsider.com - January 10 at 9:29 AM
Eiger Biopharmaceuticals (EIGR) Upgraded by Zacks Investment Research to BuyEiger Biopharmaceuticals (EIGR) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - January 9 at 11:18 PM
Eiger BioPharmaceuticals Announces Appointment of Commercial Operations Industry Veteran Eldon Mayer to its Board of DirectorsEiger BioPharmaceuticals Announces Appointment of Commercial Operations Industry Veteran Eldon Mayer to its Board of Directors
finance.yahoo.com - January 8 at 9:47 AM
Eiger Biopharmaceuticals Inc (EIGR) Receives Consensus Rating of "Buy" from BrokeragesEiger Biopharmaceuticals Inc (EIGR) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - January 5 at 7:58 AM
Eiger BioPharmaceuticals (EIGR) Reports Complete Enrollment of Phase 2 ULTRA Study of Ubenimex in Primary and Secondary Lymphedema PatientsEiger BioPharmaceuticals (EIGR) Reports Complete Enrollment of Phase 2 ULTRA Study of Ubenimex in Primary and Secondary Lymphedema Patients
www.streetinsider.com - January 4 at 5:25 PM
Reviewing Mesoblast (MESO) & Eiger Biopharmaceuticals (EIGR)Reviewing Mesoblast (MESO) & Eiger Biopharmaceuticals (EIGR)
www.americanbankingnews.com - January 4 at 11:30 AM
Eiger BioPharmaceuticals Completes Enrollment of Phase 2 ULTRA Study of Ubenimex in Primary and Secondary Lymphedema PatientsEiger BioPharmaceuticals Completes Enrollment of Phase 2 ULTRA Study of Ubenimex in Primary and Secondary Lymphedema Patients
finance.yahoo.com - January 4 at 9:24 AM
Eiger BioPharmaceuticals to Present at Biotech Showcase™ 2018 - PR Newswire (press release)Eiger BioPharmaceuticals to Present at Biotech Showcase™ 2018 - PR Newswire (press release)
www.prnewswire.com - January 3 at 5:26 PM
Eiger BioPharmaceuticals Appoints David Apelian, MD, PhD, MBA ... - PR Newswire (press release)Eiger BioPharmaceuticals Appoints David Apelian, MD, PhD, MBA ... - PR Newswire (press release)
www.prnewswire.com - January 3 at 5:26 PM
Ladenburg Thalmann Financial Services Begins Coverage on Eiger Biopharmaceuticals (EIGR)Ladenburg Thalmann Financial Services Begins Coverage on Eiger Biopharmaceuticals (EIGR)
www.americanbankingnews.com - January 3 at 9:38 AM
Eiger BioPharmaceuticals Appoints David Apelian, MD, PhD, MBA Chief Operating Officer and Executive Medical OfficerEiger BioPharmaceuticals Appoints David Apelian, MD, PhD, MBA Chief Operating Officer and Executive Medical Officer
finance.yahoo.com - January 3 at 8:36 AM
Eiger BioPharmaceuticals to Present at Biotech Showcase™ 2018Eiger BioPharmaceuticals to Present at Biotech Showcase™ 2018
finance.yahoo.com - January 2 at 9:23 AM
30 Big Biotech Events Coming in 2018 - 24/7 Wall St.30 Big Biotech Events Coming in 2018 - 24/7 Wall St.
247wallst.com - December 30 at 9:17 AM
Why Eiger BioPharmaceuticals (EIGR) Could Be Positioned for a SurgeWhy Eiger BioPharmaceuticals (EIGR) Could Be Positioned for a Surge
www.zacks.com - December 22 at 9:32 AM
Eiger Biopharmaceuticals (EIGR) Lifted to "Hold" at ValuEngineEiger Biopharmaceuticals (EIGR) Lifted to "Hold" at ValuEngine
www.americanbankingnews.com - December 21 at 11:28 PM
Eiger Biopharmaceuticals Inc (EIGR) to Post FY2017 Earnings of ($3.88) Per Share, Wedbush ForecastsEiger Biopharmaceuticals Inc (EIGR) to Post FY2017 Earnings of ($3.88) Per Share, Wedbush Forecasts
www.americanbankingnews.com - December 21 at 8:52 AM
Eiger Biopharmaceuticals Inc (EIGR) Expected to Post Earnings of -$1.07 Per ShareEiger Biopharmaceuticals Inc (EIGR) Expected to Post Earnings of -$1.07 Per Share
www.americanbankingnews.com - December 19 at 1:24 AM
Eiger BioPharmaceuticals, Inc. (EIGR) Given Consensus Recommendation of "Buy" by BrokeragesEiger BioPharmaceuticals, Inc. (EIGR) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - December 11 at 7:58 AM
Eiger BioPharmaceuticals (EIGR) PT Set at $34.00 by OppenheimerEiger BioPharmaceuticals (EIGR) PT Set at $34.00 by Oppenheimer
www.americanbankingnews.com - December 8 at 6:50 PM
Eiger BioPharmaceuticals, Inc. (EIGR) Upgraded at ValuEngineEiger BioPharmaceuticals, Inc. (EIGR) Upgraded at ValuEngine
www.americanbankingnews.com - November 26 at 1:38 PM
Eiger BioPharmaceuticals (EIGR) Presents At Jefferies 2017 London Healthcare Conference - SlideshowEiger BioPharmaceuticals (EIGR) Presents At Jefferies 2017 London Healthcare Conference - Slideshow
seekingalpha.com - November 17 at 4:58 PM
Eiger BioPharmaceuticals, Inc. (EIGR) Receives Average Recommendation of "Buy" from BrokeragesEiger BioPharmaceuticals, Inc. (EIGR) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - November 16 at 8:00 AM
Eiger BioPharmaceuticals to Present at Jefferies 2017 Healthcare ConferenceEiger BioPharmaceuticals to Present at Jefferies 2017 Healthcare Conference
finance.yahoo.com - November 13 at 11:39 AM
Eiger BioPharmaceuticals Reports Third Quarter 2017 Financial Results - PR Newswire (press release)Eiger BioPharmaceuticals Reports Third Quarter 2017 Financial Results - PR Newswire (press release)
www.prnewswire.com - November 11 at 9:13 AM
Eiger BioPharmaceuticals, Inc. (EIGR) Releases Quarterly  Earnings Results, Beats Estimates By $0.18 EPSEiger BioPharmaceuticals, Inc. (EIGR) Releases Quarterly Earnings Results, Beats Estimates By $0.18 EPS
www.americanbankingnews.com - November 10 at 7:32 PM
Eiger BioPharmaceuticals Reports Third Quarter 2017 Financial ResultsEiger BioPharmaceuticals Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 10 at 12:03 PM
Should Your Next Investment In The Healthcare Industry Be In Eiger BioPharmaceuticals Inc (EIGR)?Should Your Next Investment In The Healthcare Industry Be In Eiger BioPharmaceuticals Inc (EIGR)?
finance.yahoo.com - November 8 at 5:49 AM
Eiger BioPharmaceuticals to Participate in Upcoming Investor Conferences - PR Newswire (press release)Eiger BioPharmaceuticals to Participate in Upcoming Investor Conferences - PR Newswire (press release)
www.prnewswire.com - November 6 at 7:44 PM
Does Eiger BioPharmaceuticals Inc’s (EIGR) Debt Level Pose A Serious Problem?Does Eiger BioPharmaceuticals Inc’s (EIGR) Debt Level Pose A Serious Problem?
finance.yahoo.com - November 6 at 7:44 PM
Eiger BioPharmaceuticals to Participate in Upcoming Investor ConferencesEiger BioPharmaceuticals to Participate in Upcoming Investor Conferences
finance.yahoo.com - November 6 at 7:44 PM
Eiger BioPharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise In Full of Underwriters Option to Purchase Additional SharesEiger BioPharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise In Full of Underwriter's Option to Purchase Additional Shares
finance.yahoo.com - October 31 at 7:25 PM
Eiger BioPharmaceuticals, Inc. (EIGR) Set to Announce Quarterly Earnings on MondayEiger BioPharmaceuticals, Inc. (EIGR) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - October 30 at 9:15 AM
Eiger BioPharmaceuticals (EIGR) Prices 1.85M Offering of Common Stock at $10/ShareEiger BioPharmaceuticals (EIGR) Prices 1.85M Offering of Common Stock at $10/Share
www.streetinsider.com - October 28 at 11:31 PM
Eiger BioPharmaceuticals (EIGR) Prices 1.85M Offering of Common Stock at $10/Share - StreetInsider.comEiger BioPharmaceuticals (EIGR) Prices 1.85M Offering of Common Stock at $10/Share - StreetInsider.com
www.streetinsider.com - October 27 at 3:21 PM
Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common StockEiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - October 27 at 3:21 PM
Eiger BioPharmaceuticals (EIGR) Plans Public Offering of Common Stock - StreetInsider.comEiger BioPharmaceuticals (EIGR) Plans Public Offering of Common Stock - StreetInsider.com
www.streetinsider.com - October 27 at 4:34 AM
Eiger BioPharmaceuticals Announces Proposed Public Offering of Common StockEiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock
finance.yahoo.com - October 26 at 6:27 PM
Eiger BioPharmaceuticals, Inc. (EIGR) Receives Buy Rating from WedbushEiger BioPharmaceuticals, Inc. (EIGR) Receives Buy Rating from Wedbush
www.americanbankingnews.com - October 25 at 10:28 PM

SEC Filings

Eiger Biopharmaceuticals (NASDAQ:EIGR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Eiger Biopharmaceuticals (NASDAQ:EIGR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Eiger Biopharmaceuticals (NASDAQ EIGR) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.